Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Zibotentan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Zibotentan. Displaying page 1 of 1.
    EudraCT Number: 2018-004393-10 Sponsor Protocol Number: GN18CA068 Start Date*: 2019-07-17
    Sponsor Name:NHS Greater Glasgow & Clyde [...]
    1. NHS Greater Glasgow & Clyde
    2. University of Glasgow
    Full Title: A randomised, double-blind, placebo-controlled, cross-over trial of zibotentan in microvascular angina
    Medical condition: Microvascular Angina and impaired exercise intolerance.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10065566 Microvascular angina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-004101-32 Sponsor Protocol Number: D4325C00001 Start Date*: 2021-04-06
    Sponsor Name:AstraZeneca
    Full Title: A Phase 2b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients w...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) BG (Completed) DK (Completed) IT (Completed) ES (Restarted) SK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2021-006577-30 Sponsor Protocol Number: D4326C00003 Start Date*: 2022-09-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and...
    Medical condition: Liver cirrhosis with features of portal hypertension.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003200-39 Sponsor Protocol Number: 13/0077 Start Date*: 2014-04-01
    Sponsor Name:University College London
    Full Title: A phase II, single centre, randomised, placebo-controlled, 3-part trial to assess the safety, tolerability and efficacy of Zibotentan in patients with renal disease secondary to scleroderma
    Medical condition: Renal complications of systemic sclerosis (scleroderma renal crisis and chronic kidney disease).
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10061087 Connective tissue disorder PT
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10018124 Generalized scleroderma LLT
    16.1 100000004857 10069339 Acute kidney injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001324-18 Sponsor Protocol Number: 202100178 Start Date*: 2021-09-30
    Sponsor Name:University Medical Center Groningen
    Full Title: A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients with elevated Albuminuria: a Randomized Double Blind Cross-Over Trial
    Medical condition: Patients with elevated Albuminuria
    Disease: Version SOC Term Classification Code Term Level
    27.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    27.0 10027433 - Metabolism and nutrition disorders 10016807 Fluid retention PT
    20.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018837-23 Sponsor Protocol Number: SPON-804-10 Start Date*: 2010-12-06
    Sponsor Name:Cardiff University
    Full Title: A randomised Phase II study of carboplatin with or without the addition of the ETAR inhibitor ZD4054 as treatment for patients with metastatic breast cancer.
    Medical condition: Metastatic Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012151-23 Sponsor Protocol Number: SPON 671-09 Start Date*: 2009-11-11
    Sponsor Name:Cardiff University
    Full Title: A randomised phase II study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer ...
    Medical condition: Metastatic Colorectal Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007623-40 Sponsor Protocol Number: D4320C00035 Start Date*: 2008-09-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-blind, Placebo-Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 in Combination with Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients with Non-small C...
    Medical condition: Locally advanced or metastatic Non small cell lung cancer (NSCLC) without predominantly squamous cell histology
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066490 Progression of non small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) CZ (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003228-39 Sponsor Protocol Number: D4320C00033 Start Date*: 2008-02-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metasta...
    Medical condition: hormone-resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) NL (Completed) GB (Prematurely Ended) FR (Completed) CZ (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) PT (Prematurely Ended) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003224-38 Sponsor Protocol Number: D4320C00015 Start Date*: 2007-12-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer ...
    Medical condition: Hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) GB (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) SE (Completed) FI (Prematurely Ended) PT (Prematurely Ended) HU (Completed) DK (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) IE (Prematurely Ended) LV (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006068-12 Sponsor Protocol Number: D4320C00036 Start Date*: 2009-08-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 plus Carboplatin and Paclitaxel or Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian C...
    Medical condition: Patients with advanced ovarian cancer who have relapsed following first-line platinum containing therapy (Patients may have received any other chemotherapy agent with the platinum agent). Relapse m...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 22:00:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA